HEALTHCARE RESOURCE UTILIZATION AND COSTS IN HR+/HER2- BREAST CANCER: EVIDENCE FROM MEXICO
Author(s)
Leticia A. Lopez Cuapio, BS1, Luis Ortiz-Blas, MSc2, Ana Paredes, BS2, Jofre Tarrago, MD3, Lourdes Barrios, MSc, MD4, Jimena Iglesias, MD5, Diego Perez, QFB6, Monica Arboleya, MD3, Celtzin Bonilla, BS3.
1STRATEGY ACCESS MANAGER, NOVARTIS, Ciudad de Mexico, Mexico, 2TIS, Mexico, Mexico, 3NOVARTIS, Mexico, Mexico, 4TECNOLOGIA E INFORMATICA PARA LA SALUD S.A. DE C.V., Mexico, Mexico, 5Sináptica RWE, Mexico, Mexico, 6Sinaptica, Mexico, Mexico.
1STRATEGY ACCESS MANAGER, NOVARTIS, Ciudad de Mexico, Mexico, 2TIS, Mexico, Mexico, 3NOVARTIS, Mexico, Mexico, 4TECNOLOGIA E INFORMATICA PARA LA SALUD S.A. DE C.V., Mexico, Mexico, 5Sináptica RWE, Mexico, Mexico, 6Sinaptica, Mexico, Mexico.
OBJECTIVES: In Mexico, breast cancer was the leading cause of death from malignant tumors among women in 2024, with HR+/HER2- subtype being the most prevalent. This study estimated healthcare resource utilization and average per-patient costs of HR+/HER2- high risk breast cancer across clinical stages, reflecting current clinical practice in leading public and private institutions in Mexico
METHODS: Twenty interviews were conducted with breast cancer-specialized physicians (16 public, 4 private). Half addressed diagnosis and early-stage disease; the remainder covered locally advanced and metastatic/recurrent disease. Unit costs were obtained from public hospital tariffs and consolidated procurement, and from specialized pharmacies, laboratories and private hospitals for the private sector. All costs were expressed in 2026 Mexican Pesos (MXN). Direct medical costs were estimated based on each physician’s reported practice e patterns and aggregated as sector-specific and overall simple means.
RESULTS: HR+/HER2- biomarkers were present in 62% of breast cancer patients; 26% were diagnosed at early stage, 50% at a locally advanced, and 23% at a metastatic/recurrent stage, with similar distributions across sectors. Resource use varied substantially between sectors and across institutions. Mean annual direct medical cost per patient increased with disease stage: MXN $49,845 at diagnosis (public $39,710; private $89,291), $737,110 at early stage (public $590, 090; private $1,325,188), $926,490 at locally advanced stage (public $613,399; private $2,178,856), and $1,273,792 at metastatic/recurrent stage (public $1,030,016; private $2,248,897). Private-sector costs were consistently ~2.2-3.6 times higher than public-sector costs. Relative to early-stage disease, costs were 26% higher at the locally stage and 73% higher at the metastatic/recurrent stage.
CONCLUSIONS: Direct medical costs escalated sharply with disease progression, with striking disparities between sectors. These findings support investment in timely diagnosis and early treatment strategies to reduce the long-term economic burden of HR+/HER2- breast cancer in Mexico
METHODS: Twenty interviews were conducted with breast cancer-specialized physicians (16 public, 4 private). Half addressed diagnosis and early-stage disease; the remainder covered locally advanced and metastatic/recurrent disease. Unit costs were obtained from public hospital tariffs and consolidated procurement, and from specialized pharmacies, laboratories and private hospitals for the private sector. All costs were expressed in 2026 Mexican Pesos (MXN). Direct medical costs were estimated based on each physician’s reported practice e patterns and aggregated as sector-specific and overall simple means.
RESULTS: HR+/HER2- biomarkers were present in 62% of breast cancer patients; 26% were diagnosed at early stage, 50% at a locally advanced, and 23% at a metastatic/recurrent stage, with similar distributions across sectors. Resource use varied substantially between sectors and across institutions. Mean annual direct medical cost per patient increased with disease stage: MXN $49,845 at diagnosis (public $39,710; private $89,291), $737,110 at early stage (public $590, 090; private $1,325,188), $926,490 at locally advanced stage (public $613,399; private $2,178,856), and $1,273,792 at metastatic/recurrent stage (public $1,030,016; private $2,248,897). Private-sector costs were consistently ~2.2-3.6 times higher than public-sector costs. Relative to early-stage disease, costs were 26% higher at the locally stage and 73% higher at the metastatic/recurrent stage.
CONCLUSIONS: Direct medical costs escalated sharply with disease progression, with striking disparities between sectors. These findings support investment in timely diagnosis and early treatment strategies to reduce the long-term economic burden of HR+/HER2- breast cancer in Mexico
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HPR184
Topic
Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Public Spending & National Health Expenditures
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Reproductive & Sexual Health